This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barrios, V. Articles by Fernandez, R. Search for Related Content PubMed PubMed Citation Articles by Barrios, V. Articles by Fernandez, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Social Bookmarking                         What's this?

Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study

Department of Cardiology, Hospital Ramon y Cajal, Madrid, vbarriosa{at}meditex.es, vbarrios.hrc{at}salud.madrid.org

Carlos Escobar

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Alberto Calderon

Primary Health Care Centre Rosa de Luxemburgo, Madrid

Juan Pablo Tomás

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Soledad Ruiz

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Jose Luis Moya

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Alicia Megias

Department of Cardiology, Hospital Ramon y Cajal, Madrid

Onofre Vegazo

AstraZeneca Medical Department, Madrid, Spain

Raul Fernandez

AstraZeneca Medical Department, Madrid, Spain

The VIPE study was a prospective, non-comparative, open-label clinical evaluation of 97 hypertensive patients (69.1% female; 68.9±9.5 years; mean blood pressure (BP) 160±12/90±9 mmHg) with echocardiographic evidence of left ventricular hypertrophy (LVH). Patients were treated for six months with a candesartan-based regimen (8 mg/16 mg + HCTZ 12.5 mg + additional drugs to lower BP < 140/90 mmHg). After six months, systolic/diastolic BP was decreased by 19.3±8/9.4±5 mmHg (p<0.001 for both), and left ventricular mass index (LVMI) decreased 17.01 g/m2 (95%CI: -13.2 to -20.99; p<0.001). During treatment with the candesartan-based regimen all echocardiographic parameters related to LVMI were significantly reduced and 28% achieved a target LVMI [< 134 g/m2 (men) and < 110 g/m² (women) ]. No significant changes were observed in ejection fraction, shortening fraction or LV diastolic function. Univariate analysis showed that both age (p=0.03) and diabetes (p=0.029) were predictive of LVH regression.

Thus, a candesartan-based regimen for six months significantly reduced echocardiographic LVH in hypertensive patients in general practice. The drug was very well tolerated and no serious adverse events were reported.

Key Words: candesartan hypertension left ventricular hypertrophy • regression

References

• European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 2003;21:1011-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Levy D., Garrison RJ, Savage DD, Kannel WB, Castelli WP Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.[Abstract]
• Verdecchia P., Schillacci G., Borgioni C. et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.[Abstract/Free Full Text]
• Okin PM, Devereaux RB, Julius J. et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The LIFE Study. Circulation 2003,108:684-90.[Abstract/Free Full Text]
• Okin PM, Devereaux RB, Julius J. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of mayor cardiovascular events. JAMA 2004;292:2343-9.[Abstract/Free Full Text]
• Verdecchia P., Angeli F., Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16:895-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mathew J., Sleight P., Lonn E. et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615-21.[Abstract/Free Full Text]
• Schneider MP, Klingbeil AU, Delles C. et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension 2004;44:61-6.[Abstract/Free Full Text]
• Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Everett AD, Tufro-McReddie A., Fisher A., Gomez RA Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension 1994;23:587-92.[Abstract/Free Full Text]
• Yamakawa T., Tanaka S., Numaguchi K. et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000;35:313-18.[Abstract/Free Full Text]
• Dahlof B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001;14:174-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Israili ZH Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14(suppl 1):S73-S76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Klingbeil AV, Schneider M., Martus P., Messerli FH, Schmieder RE A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cuspidi C., Muiesan ML, Valagussa L. et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20:2293-300.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Devereux RB, Dahlof B., Gerdts E. et al. Regression of hypertensive left ventricular hypertorphy by losartan compared with atenolol. The Losartan Intervention For Endpoint reduction in hypertensive (LIFE) Study. Circulation 2004;110:1456-62.[Abstract/Free Full Text]
• Malmqvist K., Kahan T., Edner M. et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Trenkwalder P. Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Press (suppl) 2000;1:27-30.[Medline] [Order article via Infotrieve]
• Hashimoto Y., Kurosawa Y., Minami K., Fushimi K., Narita H. A novel angiotensin II-receptor antagonist, 606A, induces regression of cardiac hypertrophy, augments endothelium-dependent relaxation and improves renal function in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol 1998;76:185-92.[CrossRef][Medline] [Order article via Infotrieve]
• Zannad F. Preserving target-organ function with candesartan cilexetil in patients with hypertension. Blood Press (suppl) 2000;1:36-9.[Medline] [Order article via Infotrieve]
• Isobe N., Taniguchi K., Oshima S. et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002;66:993-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002;62:1253-87. 23. Concato J., Shah N., Horwitz RI Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92.[Abstract/Free Full Text]
• Rosser WW Application of evidence from randomised controlled trials to general practice. Lancet 1999;353:661-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-18.[Abstract/Free Full Text]
• Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Sachas I. Echocardiographic assessment of left ventricular hypertrophy comparison to necropsy findings. Am J Cardiol 1986;57:450-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ganau A., Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol 1992;19:1550-58.[Abstract]
• Nosir YF, Vletter WB, Boersma E. et al. The apical long-axis rather than the two-chamber view should be used in combination with the four-chamber view for accurate assessment of left ventricular volumes and function. Eur Heart J 1997;18:1175-85.[Abstract/Free Full Text]
• Sokolow M., Lyon TP The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Casale PN, Devereux RB, Kligfield P. et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985;6:572-80.[Abstract]
• Casale PN, Devereux RB, Alonso DR, Campo E., Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 1987;75:565-72.[Abstract/Free Full Text]
• Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992;20:1180-86.[Abstract]
• Thurmann PA, Kenedi P., Schmidt A. et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42.[Abstract/Free Full Text]
• Anan F., Takahashi N., Ooie T., Hara M., Yoshimatsu H., Saikawa T. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 2004;53:777-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Koren MJ, Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.[Abstract/Free Full Text]
• Spratt JC, Webb DJ, Shiels A., Williams B. Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. JRAAS 2001;2:227-32.[Medline] [Order article via Infotrieve]
• Bella JN, Devereux RB Is echocardiography essential in the management of newly diagnosed hypertension? Am J Hypertens 2006;19:1156-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Okin PM, Devereux RB, Gerdts E. et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006;113:1588-96.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 4, 236-242 (2006)
DOI: 10.3317/jraas.2006.044


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. Barrios, C. Escobar, A. Calderon, R. Echarri, S. Barrios, and J. Navarro-Cid Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 168 - 173. [Abstract] [PDF]

				C. Escobar and V. Barrios Gender Differences in Left Ventricular Hypertrophy Regression Hypertension, June 1, 2008; 51(6): e58 - e58. [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barrios, V. Articles by Fernandez, R. Search for Related Content PubMed PubMed Citation Articles by Barrios, V. Articles by Fernandez, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Social Bookmarking                         What's this?